646066-59-3

Basic information

• Product Name: XLI 093
• Synonyms: XLI 093;bis[8-ethynyl-5,6-dihydro-5-methyl-6-oxo-4h-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylic acid]1,3-propanediyl ester hydrate
• CAS NO: 646066-59-3
• Molecular Formula: C33H26N6O6
• Molecular Weight: 602.6
• Mol File: 646066-59-3.mol
• Article Data: 3

Chemical Properties

• Appearance: off-white/powder
• Storage Temp.: 2-8°C
• Solubility: DMSO: ~16 mg/mL
• CAS DataBase Reference: XLI 093(CAS DataBase Reference)
• NIST Chemistry Reference: XLI 093(646066-59-3)
• EPA Substance Registry System: XLI 093(646066-59-3)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 646066-59-3(Hazardous Substances Data)

Usage

Uses

Xli 093 is selective α5 GABAA receptor antagonist.

Upstream product

• 646066-60-6 8-ethynyl-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]-benzodiazepine-3-carboxylic acid 
• 504-63-2 trimethyleneglycol 
• 78756-36-2 7-bromo-3,4-dihydro-4-methyl-2H-1,4-benzodiazepine-2,5-(1H)-dione 
• 3415-35-8 4-methyl-3H-1,4-benzodiazepine-2,5-(1H,4H)-dione 
• 78756-37-3 ethyl 8-bromo-5-methyl-6-oxo-5,6-dihydro-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-carboxylate 
• 173990-13-1 [3H]-RY 80 
• 173990-10-8 ethyl 5-methyl-6-oxo-8-((trimethylsilyl)ethynyl)-5,6-dihydro-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-carboxylate 

Relevant articles and documents

Synthesis, in Vitro Affinity, and Efficacy of a Bis 8-Ethynyl-4H-imidazo[1,5a]-[1,4]benzodiazepine Analogue, the First Bivalent α5 Subtype Selective BzR/GABAA Antagonist

The synthesis and in vitro affinity of the α5β3γ2 (α5) subtype selective BzR/GABAA antagonist 7 is described. This ligand is selective for α5 subtypes in vitro and is a potent antagonist of the effects of diazepam only at α5β3γ2 subtypes (oocytes). Ligands such as 7 will be important in the determination of which physiological function(s) are subserved by this GABAA α5 subtype.

GABAERGIC AGENTS TO TREAT MEMORY DEFICITS

The present invention provides molecules and methods for the prevention and/or treatment of memory deficit related conditions and/or enhancement of cognizance. In a preferred embodiment, the invention includes compounds, salts and prodrugs thereof for the prevention and/or treatment of these conditions.